Answers are grounded in this paper and cite their sources.
Cancer remains one of the most fatal diseases worldwide, causing millions of deaths every year. Immunotherapy is a major, groundbreaking approach that offers hope for durable responses to cancer treatment. Despite the initial success of cancer immunotherapy, its clinical utility is often limited by several patient-related factors, such as the immunosuppressive tumor microenvironment (TME). Nanotechnology has emerged as a powerful tool to address these obstacles and potentiate the effectiveness of immunotherapy. Nanomedicine, due to its versatile design and tunable flexible characteristics are widely used to modulate the immune responses. These are generally designed to interact with immune cells such as tumor-associated macrophages, T cells, dendritic cells, Chimeric Antigen Receptor (CAR) T cells, and neutrophils, aiming to further modulate the TME. This review focuses on recent advances in nanotechnology-driven strategies for immunomodulation and their role in TME-associated immunotherapy.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: